Skip to main content

Table 5 Outcomes in the cohort during the follow-up period of up to 23 years

From: Comparison of clinical outcomes in patients undergoing mitral valve replacement with mechanical or biological substitutes: a 20 years cohort

Variable Sample (n = 352) n (%) Mechanical prosthesis (n = 247) n (%) Biological prosthesis (n = 105) n (%) p
Reoperation for valve replacement 33 (9.4) 16 (6.5) 17 (16.2) 0.008
Bleeding events 23 (6.5) 18 (7.3) 5 (4.8) 0.521
Thromboembolic events 7 (2.0) 5 (2.0) 2 (1.9) 1.000
Total number of deaths 91 (25.9) 52 (21.1) 39 (37.1) 0.003
Perioperative death 21 (6.0) 10 (4.0) 11 (10.5) 0.037
ICU* 9 (2.6) 4 (1.6) 5 (4.8) 0.133
Hospital* 11 (3.1) 5 (2.0) 6 (5.7) 0.092
Others** 70 (19.9) 42 (17.0) 28 (26.7) 0.053
  1. ICU, intensive care unit; *none exceeded the perioperative period; **deaths after 30 days of hospitalization.
  2. A significantly higher incidence of reoperation for valve replacement (p = 0.008) and death (p = 0.003) was found in patients who underwent biological valve replacement (Table 5).